Chardan Capital analyst Keay Nakae maintained a Buy rating on Emergent Biosolutions (EBS) today. The company’s shares closed last Friday at $97.23.
According to TipRanks.com, Nakae is a 5-star analyst with an average return of 27.9% and a 50.0% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Lineage Cell Therapeutics, and Arrowhead Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Emergent Biosolutions with a $98.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $137.61 and a one-year low of $46.37. Currently, Emergent Biosolutions has an average volume of 594K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm’s products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.
